ClinicalTrials.gg
CompletedNCT01936012Updated Sep 5, 2013

Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition

An interventional study of Lisinopril 10 mg tablets of PT Dexa Medica and Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia in Healthy, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-05.

Sponsored by Dexa Medica Group · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The present study was conducted to find out whether the bioavailability of 10 mg lisinopril tablets produced by PT Dexa Medica was equivalent to the tablets produced by the innovator (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, under license from Astra Zeneca UK Ltd.)

Read the detailed description

This was a randomized, single-blind, two-period, two-sequence, cross-over study under fasting condition. The participating subjects were required to have an overnight fast and in the next morning were given orally one tablet of the test drug (Lisinopril 10 mg, produced by PT Dexa Medica) or one tablet of the reference drug (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, under license from Astra Zeneca UK Ltd.).

Blood samples were drawn immediately before taking the drug (control), and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 36, and 48 hours after drug administration. Seven days after the first drug administration (washout period), the procedure was repeated using the alternate drug.

The pharmacokinetic parameters, including AUCt, AUCinf, Cmax, t max, and t1/2, were determined from plasma concentrations of lisinopril, using liquid chromatography with tandem mass spectrometry detection (LC-MS/MS) method.

02

Conditions studied

  • Healthy

Keywords

  • Lisinopril
  • Bioequivalence
  • Bioavailability
  • Pharmacokinetic
  • Angiotensin-converting enzyme inhibitor
03

In context

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects.
  • Aged 18 - 55 years inclusive.
  • Non-smokers or moderate smokers (less than 10 cigarettes per day).
  • Able to participate, communicate well with the investigators and willing to provide written to participate in the study.
  • within 18 to 25 kg/m2.
  • Vital signs (after 10 minutes rest) were within the following ranges:

    • systolic blood pressure 110 - 120 mmHg
    • diastolic blood pressure 70 - 80 mmHg
    • pulse rate 60 - 90 bpm

Exclusion criteria

Exclusion Criteria:

  • Personal/family history of allergy or or to lisinopril or allied drugs.
  • Pregnant or lactating women.
  • Any major illness or ongoing chronic medical illness in the past 90 days.
  • Any clinically significant abnormality of liver function test (, AP, total >= 1.5 ).
  • Any clinically significant abnormality of renal function test (serum creatinine concentration > 1.4 mg/dL).
  • Positive surface antigen (HBsAg), anti-, or anti-.
  • Clinically significant hematology abnormalities.
  • Clinically significant (ECG) abnormalities.
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug.
  • Past history of anaphylaxis or angioedema.
  • History of drug or alcohol abuse within 12 months prior to screening.
  • Participation in any clinical trial within the past 90 days.
  • History of any bleeding or coagulative disorders.
  • History of difficulty with donating blood or accessibility of veins in left or right arm.
  • A donation or loss of 500 mL (or more) of blood within 3 months before the study's first dosing day.
  • Intake of any prescription or non-prescription drugs, food supplements, or herbal medicines within 14 days of the study's first dosing day.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Lisinopril 10 mg tablets of PT Dexa Medica

    Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.

    Drug: Lisinopril 10 mg tablets of PT Dexa Medica

  • Active comparator
    Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia

    Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.

    Drug: Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia

Interventions

  • Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

    Also known as: Test Product: Lisinopril 10 mg tablets of PT Dexa Medica

  • Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

    Also known as: Reference product: Zestril® 10 mg, produced by PT Boehringer Ingelheim Indonesia, under license from Astra Zeneca UK Ltd..

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time zero to the last observed quantifiable concentration (AUCt) of lisinopril

    Relative bioavailability (primarily measured by AUCt and AUCinf) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition. AUCt was determined from plasma concentration of lisinopril.

    Time frame: 48 hours

  2. Area under the plasma concentration-time curve from time zero to infinity (AUCinf) of lisinopril

    Relative bioavailability (primarily measured by AUCt and AUCinf) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition. AUCinf was determined from plasma concentration of lisinopril.

    Time frame: 48 hours

Secondary outcomes

  1. The peak plasma concentration (Cmax) of lisinopril

    Relative bioavailability (secondarily measured by Cmax) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition. Cmax was determined from plasma concentration of lisinopril.

    Time frame: 48 hours

  2. Time needed to achieve the peak plasma concentration (t max) of lisinopril

    Relative bioavailability (secondarily measured by t max) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition. t max was determined from plasma concentration of lisinopril.

    Time frame: 48 hours

  3. The elimination half-life (t1/2) of lisinopril

    Relative bioavailability (secondarily measured by t1/2) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition. t1/2 was determined from plasma concentration of lisinopril.

    Time frame: 48 hours

07

Study locations

1 site
  • PT Equilab International
    Jakarta, 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2013
First posted
Sep 5, 2013
Start
Feb 2013
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Sep 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01936012
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Sep 5, 2013
Start date
Feb 2013
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Sep 5, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisinopril

Start the discussion